Phase III trial on nadofaragene firadenovec for high-grade, BCG unresponsive NMIBC patients

Dr. Boorjian (US) on “Safety and efficacy of intravesical nadofaragene firadenovec for patients with high-grade, BCG unresponsive nonmuscle invasive bladder cancer (NMIBC): Results from a phase III trial.”